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Background: Enterococcus faecium has recently emerged as a multidrug-resistant nosocomial pathogen involved
in outbreaks worldwide. A high rate of resistance to different antibiotics has been associated with virulent clonal
complex 17 isolates carrying the esp and hyl genes and the purK1 allele.
Results: Twelve clinical vancomycin-resistant Enterococcus faecium (VREF) isolates were obtained from pediatric
patients at the Hospital Infantil de México Federico Gómez (HIMFG). Among these VREF isolates, 58.3% (7/12) were
recovered from urine, while 41.7% (5/12) were recovered from the bloodstream. The VREF isolates showed a 100%
rate of resistance to ampicillin, amoxicillin-clavulanate, ciprofloxacin, clindamycin, chloramphenicol, streptomycin,
gentamicin, rifampicin, erythromycin and teicoplanin. In addition, 16.7% (2/12) of the isolates were resistant to
linezolid, and 66.7% (8/12) were resistant to tetracycline and doxycycline. PCR analysis revealed the presence of the
vanA gene in all 12 VREF isolates, esp in 83.3% (10/12) of the isolates and hyl in 50% (6/12) of the isolates. Phylogen-
etic analysis via molecular typing was performed using pulsed-field gel electrophoresis (PFGE) and demonstrated
44% similarity among the VREF isolates. MLST analysis identified four different sequence types (ST412, ST757, ST203
and ST612).
Conclusion: This study provides the first report of multidrug-resistant VREF isolates belonging to clonal complex
17 from a tertiary care center in Mexico City. Multidrug resistance and genetic determinants of virulence confer
advantages among VREF in the colonization of their host. Therefore, the prevention and control of the spread of
nosocomial infections caused by VREF is crucial for identifying new emergent subclones that could be challenging
to treat in subsequent years.
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Enterococci are opportunistic pathogens of the normal
intestinal microbiota of humans and animals [1,2]. The
most common species of Enterococcus involved in
nosocomial infections is Enterococcus faecium (E. fae-
cium) [1,2]. This pathogen is associated with hospital-
acquired infections such as UTIs (urinary tract infections),
wounds, bacteremia, endocarditis and meningitis [1,2].
In recent years, the emergence of multidrug-resistant
E. faecium has increased [3-5]. The recommended treat-
ment for Enterococcus infections has been penicillin
alone or combined with aminoglycosides. However, due
to increased resistance to aminoglycosides, vancomycin
is currently the antibiotic employed to treat these infec-
tions. In the last several decades, the number of
vancomycin-resistant enterococci (VRE) has increased.
The first VRE isolates were reported in the United King-
dom in the late 1980s [6]. In the United States, more
than 80% of E. faecium isolates from hospitals are now
resistant to vancomycin, and virtually all of them (>90%)
exhibit ampicillin resistance [7]. Vancomycin-resistant
Enterococcus faecium (VREF) has been associated with
outbreaks in hospitals worldwide [2]. The rates of VREF
colonization and infection have risen steadily, with most
cases being caused by strains displaying glycopeptide
resistance to VanA and VanB [8-11].
In addition to multidrug resistance, E. faecium pro-
duces diverse factors that contribute to its pathogenesis,
including virulence molecules such as secreted antigen
SagA [12], cell wall-anchored collagen adhesin (Acm)
[13], hyaluronidase (Hyl) [14] and enterococcal surface
protein (Esp) [15]. However, the traits that contribute to
the transition of E. faecium from a commensal to a
nosocomial pathogen have not been identified [16].
Molecular typing methods are essential for identifying
hospital-associated outbreaks of E. faecium. Multilocus
sequence typing (MLST) has revealed the existence of
host-specific genogroups, including a specific genetic
lineage designated clonal complex 17, associated with
hospital-related isolates [1,17]. MLST of E. faecium is
based on identifying alleles from DNA sequences in in-
ternal fragments of housekeeping genes (atpA, ddl, gdh,
purK, gyd, pstS and adk), resulting in a numeric allelic
profile, with each profile then being assigned a sequence
type (ST) [17].
Complex 17 most likely evolved from the primary
E. faecium ancestor ST-22, while ST-17 represents an
important secondary founder with additional linages
designated to complex 17 [18]. Clonal complex 17 is
characterized by ampicillin and quinolone resistance and
the presence of a putative pathogenicity island that in-
cludes the esp and/or hyl genes in the majority of iso-
lates [1,18-20]. Various STs belonging to clonal complex
17, such as ST16, ST17, ST18, ST203 and ST412, arecurrently being disseminated worldwide [21,22]. Inter-
estingly, half of the STs within the clonal complex 17
polyclonal subpopulation have also been identified in
samples obtained from healthy humans, swine, poultry
and pets [16].
In Mexico, there is little available information about
the prevalence of VREF isolates, and no study related to
clonal complex 17 has been performed in pediatric
patients. The aim of this study was to genotypically
and phenotypically characterize VREF clinical isolates
from 12 immunocompromised pediatric patients at the
Hospital Infantil de México Federico Gómez (HIMFG).
This study involved amplification of the resistance genes
vanA and vanB and two virulence genes (esp and hyl)




Twelve E. faecium isolates of clinical importance were
obtained from 12 patients with nosocomial infections in
the PICU (Pediatric Intensive Care Unit), oncology,
gastroenterology and transplant wards of HIMFG during
the period from July 2009 to April 2011. The isolates
were maintained at −70°C in skim milk (Becton
Dickinson, New Jersey, USA) and cultured on 5% sheep
blood agar plates (Becton Dickinson, New Jersey, USA)
at 37°C under 5% CO2 for 24 h. The E. faecalis ATCC®
29212, E. faecalis ATCC® 51299 and E. faecium ATCC®
51559 strains (American Type Culture Collection Ma-
nassas, VA, USA) were used as controls.
Biochemical tests
Bacteria were grown on blood agar, and identification
was performed using manual methods. All colonies
were grown in brain heart infusion broth (BHI) (Becton
Dickinson, New Jersey, USA) with 6.5% NaCl and on
bile esculin agar (Oxoid Sunnyvale, California, USA) to
determine their hydrolysis grade. Disks impregnated
with the substrate L-pyrrolidonyl-beta-naphthylamide
were used to perform pyrrolidonase tests (Oxoid Bio-
chemical Identification System, Oxoid LTD., Basing-
stoke, Hampshire, England). Reduction of tellurite
(Merck, Darmstadt, Germany) was evaluated via growing
the bacteria on 0.04% potassium tellurite.
Antibiotic susceptibility
The antibiotic susceptibility profiles of the 12 VREF
isolates were determined via the minimum inhibitory
concentration (MIC) technique by means of the micro-
dilution method using Mueller-Hinton broth (MHB),
as recommended by the Clinical and Laboratory
Standards Institute. MIC tests were performed for
vancomycin (MP Biomedicals, Solon, Ohio, USA),
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chloramphenicol (MP Biomedicals, Solon, Ohio, USA),
ciprofloxacin (MP Biomedicals, Solon, Ohio, USA),
streptomycin (Alexis Biochemical, San Diego California,
USA), linezolid (Sigma-Aldrich, St. Louis, Missouri,
USA), rifampicin (MP, Biomedicals, Ohio, USA), nitro-
furantoin (MP Biomedicals, Solon, Ohio, USA), tetracyc-
line (MP Biomedicals, Solon, Ohio, USA), doxycycline
(Sigma-Aldrich, St. Louis, Missouri, USA), erythromy-
cin (MP Biomedicals, Solon, Ohio, USA), tigecycline
(Sigma-Aldrich, St. Louis, Missouri, USA), gentamicin
(MP Biomedicals, Solon, Ohio, USA) and amoxicillin-
clavulanate (Glaxo-Smith-Kline, Philadelphia, Pennsylva-
nia, USA). Several concentrations (256–0.625 μg/ml) of
the antibiotics were tested in Mueller Hinton broth, with
100 μl of those dilutions being loaded into each well of a
microplate. For each dilution, 100 μl of a bacterial sus-
pension (1.5x108 CFU/ml) was inoculated and grown
overnight at 37°C under a CO2 atmosphere. After bac-
terial growth was detected, the MIC for each isolate of
E. faecium was reported as the highest concentration
(μg/ml) of antibiotics in which no growth was observed.
The E. faecalis ATCC® 29212 strain (American Type
Culture Collection Manassas, VA, USA) was used as a
control. These isolates were also evaluated for high-level
aminoglycoside resistance (HLAR) to streptomycin
(1,000 μg/ml) and gentamicin (500 μg/ml).
Detection of the glycopeptide resistance genes vanA and
vanB
PCR was performed to detect the glycopeptide resistance
genes vanA and vanB in the 12 E. faecium clinical iso-
lates using specific primers (Table 1) [23]. Briefly, gen-
omic DNA was purified using the Wizard Genomic
DNA Purification Kit (Promega Madison, Wisconsin,
USA) from a bacterial culture grown in BHI broth incu-
bated at 37°C for 24 h. The amplification reactions were
prepared in a final volume of 50 μl, as follows: 25 μl of
amplification mix (22 mM Tris/HCl, pH 8.4; 55 mM
KCl; 1.65 mM MgCl2; 25 μM each dNTP; 0.6 U recom-
binant Taq DNA polymerase/ml), 100 ng/μl of bacterialTable 1 Primers sequences used in this study








hyl-R AGGCTCCAATTCTGTDNA, 10 μl of H2O and 5 μl of primer solution (10 pg/
μl). A Perkin Elmer 9600 thermocycler was programmed
to run for 30 cycles with the following parameters:
denaturing at 94°C for 3 m, annealing at 55°C for 45 s
and extension at 72°C for 1 m, with a final extension at
72°C for 2 m. The samples were analyzed via electro-
phoresis in 1% agarose gels (Agarose LE, Promega) using
a 100 bp DNA ladder (Gibco/BRL Life Technologies,
Breda, The Netherlands). E. faecium strain ATCC 51559
(vanA+) and E. faecalis strain ATCC® 51299 (vanB+)
were used as controls in the PCR experiments [24].PCR screening for the esp and hyl genes
DNA from bacterial cultures was extracted and ampli-
fied via PCR using primers for the espEfm and hylEfm
genes (Table 1), generating bands of 954 bp and 661 bp,
respectively [14,25].Molecular typing of VREF
PFGE of the 12 VREF clinical isolates was carried out
following the protocols of Morrison et al. [26,27]. Briefly,
the samples were digested with 50 U of SmaI (New
England Biolab, Ipswich, MA, USA) for 4 h at 25°C. The
digested plugs were separated via electrophoresis in 1%
agarose gels (BioRad, Hercules, California, USA) using
ultra-pure DNA agarose (BioRad, Hercules, California,
USA), with 0.5X TBE as the running buffer in the
CHEF MAPPER system (BioRad Laboratories, Hercules,
California, USA), run at 6 V/cm at 14°C under two dif-
ferent linear ramped pulse times: 1 to 10 s for 16 h and
10 to 40 s for 22 h. A PFGE lambda ladder (New
England Biolabs, Hertfordshire, England, UK) was used
as a molecular weight marker, and the gels were stained
for 40 m with 0.5 mg/ml of ethidium bromide for
visualization under UV light. The obtained banding pat-
terns were initially interpreted via visual inspection ac-
cording to the criteria specified by Tenover et al. [28].
Cluster analysis was performed with BioNumerics
(Applied Maths, Inc., Austin, TX, USA) using the DICE
correlation coefficient and the unweighted pair groupSize (bp) Reference
ATA 1,030 (Clark et al., 1993) [23]
CAA
GA 433 (Clark et al., 1993) [23]
A
CC 945 (Shankar et al., 1999) [25]
GA
C 661 (Rice et al., 2003) [14]
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ing method [29].
The PFGE pulsotypes of the 12 VREF clinical isolates
were also genotyped through multilocus sequence typing
(MLST) according to a standard protocol described by
Homan et al. [17]. Fragments of seven housekeeping
genes (atpA, ddl, gdh, purK, gyd, pstS and adk) were se-
quenced using a 3730xl DNA Analyzer (Applied Biosys-
tems, Foster City, California, USA), thus obtaining their
allelic profiles, and the STs for each unique allelic profile
were designated on the basis of information from the
MLST website (http://efaecium.mlst.net).
Results
Origin of the strains
A total of 12 VREF clinical isolates obtained during the
period from July 2009 to April 2011 were included in
this study. The risk factors of the 12 patients were char-
acterized by a minimum hospital stay of 4 days, assist-
ance in the PICU and treatment with vancomycin.
During their stay, the 12 patients were subjected to sur-
gical procedures and received a central venous catheter,
steroids and immunosuppressive treatment. Among the
VREF isolates, 58.3% (7/12) were obtained from urine,
while 41.6% (5/12) were obtained from the bloodstream.
The VREF isolates were obtained from patients with dif-
ferent pathologies (Table 2).
Detection of susceptibility patterns and glycopeptide
resistance in the VREF isolates
The results obtained for the 12 VREF clinical isolates
showed a 100% rate of resistance to ampicillin, amoxicil-
lin-clavulanate, ciprofloxacin, clindamycin, chlorampheni
col, streptomycin, gentamicin, rifampicin, erythromycinTable 2 Characteristics of the 12 VREF isolates related to the
ward, PFGE, sequence type and clonal complex
Clinical isolate Clinical diagnosis
133H Acute lymphocytic leukemia L1, fever, and neutropeni
926U Aplastic anemia, neutropenic colitis, septic shock
821U Lupus erythematosus, septic Shock
851H Anaplastic lymphoma, tumor lysis syndrome, sepsis
215H Venous catheter infection, Down syndrome
222U Acute myeloid leukemia M2, tumor lysis syndrome, Septic
127U Acute lymphocytic leukemia L1, fever, and neutropeni
30H Wilms tumor
634U Septic shock, hemophagocytic lymphohistiocytosis
459U Lupus erythematosus, sacroiliac ulcers
422H Acute myeloid leukemia M4, fever, and neutropenia
155U cholestatic syndrome, choledochal cyst.
Multilocus sequence typing (MLST), sequence types (STs), clonal complex (CC). ONC
SS (Short Stay Ward) and GST (Gastroenterology Ward).and teicoplanin. The MIC values for each VREF isolate
are presented in Table 3. In addition, 16.7% (2/12) of the
VREF clinical isolates were resistant to linezolid, and
67% (8/12) were resistant to tetracycline and doxycycline
(Table 3). However, all of the VREF isolates were suscep-
tible to nitrofurantoin and tigecycline (Table 3).
The HLAR values for gentamicin (500 μg/ml), strepto-
mycin (1,000 μg/ml) and gentamicin/streptomycin (500/
1,000 μg/ml) were determined with to 50% (6/12), 25%
(3/12) and 25% (3/12), respectively.
The vanA and vanB genes of the 12 VREF clinical iso-
lates were amplified via PCR. Interestingly, only the
vanA gene was detected in all the VREF clinical isolates,
as a 1,030 bp amplicon (data not shown), whereas
the vanB gene, with a length of 433 bp, was not identi-
fied in the isolates (data not shown). The E. faecium
ATCC® 51559 (vanA+) and E. faecalis ATCC® 51299
(vanB+) strains were used as positive controls in the
PCR assays [24].Prevalence of the esp and hyl virulence genes in the VREF
isolates
The esp and hyl virulence genes, which are associated
with a clonal subcluster known as clonal complex 17
in VREF clinical isolates, were detected via PCR. The
esp and hyl genes were highly prevalent in the iso-
lates. The esp virulence gene was detected in 83.3%
(10/12) of the isolates, and the hyl virulence gene
was present in 50% (6/12) of them. Therefore, three
genotypes were determined for the VREF clinical iso-
lates: esp+/hyl-, esp+/hyl+ and esp-/hyl+, at prevalence
rates of 50% (6/12), 33.3% (4/12) and 16.7% (2/12),
respectively.patients’ clinical diagnosis, source of clinical samples,
Sources of clinical samples Wards PFGE MLST/STs CC
a Bloodstream ONC A 757
Urine ONC A 203 17
Urine TRPU A 412 17
Bloodstream PICU B 757
Bloodstream PICU B 612 17
shock Urine ONC B 412 17
a. Urine PICU B1 412 17
Bloodstream PICU B1 412 17
Urine ONC C 757
Urine PICU C 412 17
Bloodstream SS D 412 17
Urine GST D 203 17
(Oncology Ward), TRPU (Transplant Unit), PICU (Pediatric Intensive Care Unit),




Am Amc CIP CC C GM S RA E Va TEI Te D LZN F/M TGC
133H 128 128 512 128 64 32 512 4 32 512 16 1 1 1 8 2
926U 256 256 4 128 32 32 64 4 32 512 32 64 8 2 2 2
821U 128 128 256 256 32 32 32 32 32 256 128 64 64 2 16 1
851H 128 128 512 256 32 32 ≥512 4 32 512 16 2 1 4 16 2
215H 128 128 512 256 32 32 ≥512 4 32 512 16 2 0.25 1 4 1
222U 64 128 256 256 32 32 32 16 32 256 32 64 16 2 32 1
127U 128 128 256 256 32 32 32 32 32 256 64 64 16 8 32 2
30H 128 128 256 256 32 32 32 16 32 256 256 64 16 1 16 2
634U 64 64 256 256 32 32 ≥512 4 32 256 16 4 0.5 2 8 2
459U 256 256 256 256 64 32 32 16 32 256 32 64 16 2 16 1
422H 128 128 256 256 32 32 32 8 32 256 64 64 8 2 16 1
155U 128 128 256 256 32 32 128 8 32 256 64 64 16 2 16 2
CVR* ≥16 ≥8 ≥4 ≥4 ≥32 ≥16 ≥16 ≥4 ≥8 ≥32 ≥16 ≥16 ≥8 ≥4 ≥128 ≥16
% R 100 100 100 100 100 100 100 100 100 100 100 67 67 16.7 0 0
Ampicillin (Am), amoxacillin/clavulanate (Amc), ciprofloxacin (CIP), clindamycin (CC), chloramphenicol (C), gentamicin (GM), streptomycin (S), rifampin (RA),
erythromycin (E), vancomycin (Va), teicoplanin (TEI), tetracycline (Te), doxycycline (D), linezolid (LZN), nitrofurantoin (F/M), and tigecycline (TGC), *Cut-off values for
resistance to MIC(μg/ml), Percentage of resistant (%R).
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PFGE and MLST
The VREF isolates were analyzed via PFGE following
SmaI digestion of genomic DNA. Data obtained through
PFGE were analyzed using a dendrogram profile, which
included the PFGE pulsotypes obtained from VREF
(Figure 1). A total of four clusters (I-IV) with five DNA
pulsotypes were identified, showing patterns consisting
of 12 to 20 DNA fragments ranging in size from 48.5 to
339.5 Kb (Figure 1). Interestingly, 25% (3/12) of the
VREF clinical isolates observed via PFGE were catego-
rized as pulsotype B and 16.7% (2/12) as pulsotype B1,
with 92% genetic similarity being observed among these
isolates (Figure 1). Meanwhile, 25% (3/12) of the VREF
isolates were classified as pulsotype A, showing a differ-
ent pattern from pulsotypes B, C and D (Figure 1). How-
ever, 16.7% (2/12) of the VREF isolates were classified as
pulsotypes C and D, which displayed 50% genetic simi-
larity. In addition, a maximum of 44% similarity was
observed among all clusters of VREF isolates.
In this study, 12 VREF clinical isolates were subjected to
MLST genotyping. Six of the 12 VREF isolates (50%)
belonged to ST412, three to ST757, two to ST203 and one
to ST612 (Table 2). eBURST analysis of the VREF isolates
revealed four different STs (ST412, ST612, ST757 and
ST203), three of which belonged to clonal complex 17;
ST757 was not related to this clonal complex (Figure 2).
Discussion
E. faecium is a highly resistant nosocomial pathogen and
has recently emerged as an important threat in hospitalsworldwide [2]. In this study, the 12 examined VREF
isolates exhibited multidrug resistance to ampicillin,
amoxicillin-clavulanate, ciprofloxacin, clindamycin, chlo-
ramphenicol, streptomycin, gentamicin, rifampicin,
erythromycin and teicoplanin. At HIMFG, several types
of enterococcal infections in pediatric patients are com-
monly treated with a combination of drugs (aminoglyco-
side-β-lactams, such as gentamicin/ampicillin) as the
first choice, while vancomycin is the second choice;
vancomycin-aminoglycoside or linezolid is the third
choice; and tigecycline is the fourth choice. Interestingly,
16.7% (2/12) of the VREF clinical isolates were also re-
sistant to linezolid, and 67% (8/12) were resistant to
both tetracycline and doxycycline. The emergence of
high levels of resistance to the most common anti-
enterococcal antibiotics (vancomycin) might constitute a
real challenge in the treatment of these infections. In the
present study, 100% (12/12) of the examined VREF iso-
lates were susceptible to tigecycline and nitrofurantoin.
The VREF resistance patterns observed in this study are
in agreement with the findings of other authors [30,31].
However, these authors observed VREF isolates that
were susceptible to linezolid and nitrofurantoin, in con-
trast to our data, which showed that two of the VREF
isolates were resistant to linezolid. Nevertheless, the low
resistance to linezolid observed in the VREF clinical iso-
lates is in accord with data reported in other countries
[11,32].
Few instances of the isolation of HLAR E. faecium
have been documented worldwide [22,33,34]. In this
study, the examined VREF clinical isolates showed
Genetic similarity 
coefficient (%)
































































































Figure 1 PFGE analysis of 12 VREF isolates recovered at HIMFG and detection of the virulence factors esp and hyl, sequence type,
isolation ward and type of sample. Phylogenetic analysis was performed using the DICE coefficient in association with the UPGMA algorithm
as the grouping method. The dendrogram was evaluated by obtaining the cophenetic correlation coefficient using the Mantel test, which
yielded an r value of 0.97769.
Ochoa et al. BMC Microbiology 2013, 13:291 Page 6 of 10
http://www.biomedcentral.com/1471-2180/13/291HLAR to gentamicin (500 μg/ml), streptomycin (1,000
μg/ml) and gentamicin/streptomycin (500/1,000 μg/ml),
displaying resistance values of 50%, 25% and 25%, respect-
ively. Treatment of severe enterococcal infection requires
combined therapy to achieve a synergistic bactericidaleffect [35]. However, the results obtained in cases of severe
infections associated with enterococci have shown that
HLAR should not be treated with combined therapy
(gentamicin/ampicillin) [35]. Therefore, the treatment of
HLAR E. faecium is restricted [36].
Figure 2 Clustering of MLST profiles using the eBURST database algorithm. Our profiles showed that ST412, ST612 and ST203, but not
ST757, belong to clonal complex 17.
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http://www.biomedcentral.com/1471-2180/13/291The enterococcal surface protein Esp, which is enco-
ded by genes that appear to have been acquired and
localized within a pathogenicity island, is commonly
found in clinical isolates and anchors to the cell wall.
This protein also affects biofilm formation and plays a
role in experimental UTI and/or endocarditis models
[2]. The presence of the esp gene has been associated
with hospital outbreaks, although this gene is not exclu-
sively found in epidemic strains [19,30,37,38]. The esp
gene was detected in 83.3% of our VREF clinical isolates.
In addition, the majority of esp+ strains of E. faecium
isolates were multidrug-resistant to more than three
antibiotics, in accord with data reported by other re-
searchers [39-41].
On the other hand, the hyl gene was found in 50% of
the VREF clinical isolates and displayed a higher preva-
lence compared to the prevalences of 29.8% (29/131)reported in isolates of E. faecium in the Picardy Region
of France, 38% (83/220) in isolates from the US and 3%
in European clinical isolates. However, in the United
Kingdom, a hyl gene prevalence of 71% (20/28) was ob-
served in E. faecium isolates [14,42,43]. We believe that
the differences observed in the detection rates of the hyl
gene are due to the region in which the samples were
isolated. The rates of the occurrence of esp+/hyl-,
esp+/hyl+ and esp-/hyl+ isolates were found to be 50% (6/
12), 33.3% (4/12) and 16.7% (2/12), respectively, which is
in accord with the findings of Vankerckhoven et al. and
Rice et al. [14,42,44]. The VREF clinical isolates of Mexi-
can origin in which the esp and/or hyl gene was amplified
(alone or together), were resistant to more than three anti-
biotics; in contrast, other studies have shown a significant
correlation between the presence of the esp gene and re-
sistance to ampicillin, imipenem and ciprofloxacin [40,41].
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native methods for the molecular characterization of
clinical isolates of E. faecium [45]. According to our
PFGE analysis, the 12 VREF isolates showed a heteroge-
neous pattern associated with a profile of multidrug re-
sistance to different antibiotics and the presence of the
vanA gene. The data obtained through PFGE revealed
four clusters (I-IV), with a low similarity of 44% being
detected among the VREF isolates and therefore high
diversity. Furthermore, the VREF isolates within clusters
I, II-B and III showed an identical banding profile in the
PFGE analysis. However, the MLST data indicated differ-
ent STs due to changes in the nucleotide sequences of
the analyzed housekeeping genes; these data are consist-
ent with the findings of Poh et al. [46]. In addition, the
VREF isolates within clusters II-B1 and IV displayed
identical PFGE and MLST profiles, in agreement with
other authors [22,33]. Nevertheless, pulsotypes from dif-
ferent wards showed similar multidrug resistance pro-
files, possibly due to horizontal genetic transference
between these isolates.
MLST is an important tool for studying the molecular
epidemiology of outbreaks of E. faecium and microbial
population biology [44]. MLST analysis of VREF clinical
isolates revealed four STs: ST203, ST412, ST612 and
ST757. As previously reported, clonal complex 17 har-
bors various STs that have been involved in hospital out-
breaks. Our results revealed two allelic profiles, ST203
and ST412, belonging to clonal complex 17 STs involved
in hospital outbreaks. However, clonal complex 17 has
been resolved into two different subgroups, one of which
harbors ST17 and ST18, while the second harbors ST78
[47]. ST17, ST18 and ST203 are the major groups in the
genetic lineage of E. faecium; they are distributed world-
wide and have been associated with outbreaks [18,48].
ST412 was the most frequent sequence type found in
the VREF isolates from HIMFG and was genetically
linked to the ST78 lineage. Interestingly, ST412 has been
identified worldwide and associated with outbreaks [49].
According to the eBURST analysis, ST612 showed char-
acteristics of the STs belonging to the 18 lineage. ST757
has not been characterized within clonal complex 17. In
addition, ST757 displayed resistance markers (ampicillin
and quinolones), virulence genes (esp+ and/or hyl+)
and the purK1 allele; however, it has not been associated
with outbreaks. Nevertheless, this community of multi-
drug-resistant strains is able to infect humans and might
contribute to the spreading of these bacteria in the
hospital, highlighting the importance of molecular typing
via MLST to identify STs involved in nosocomial
outbreaks.
Recently, it was shown that MLST analysis of typified
E. faecium based on selected alleles may generate mis-
leading results due to the recombination of five alleles(atpA, ddl, gdh, gyd and pstS). As only the purk and adk
alleles are located in regions where there is no predicted
recombination, the results must be interpreted with care
[50]. The genome of E. faecium is highly plastic due to
the few existing barriers to the acquisition of foreign
genetic elements [51,52]. Recent studies have provided
evidence of high levels of recombination through com-
parative genomics analyses [51-54]. Whole-genome se-
quencing platforms are superior to conventional typing
methods, providing an excellent tool for determining
phylogenies and regions of recombination and for
accurately discriminating between outbreak- and non-
outbreak-causing VREF isolates [50,55]. Thus, whole-
genome sequence information, rather than data on just
one or a few genes, could be used to distinguish between
closely related strains.
In this study, MLST and PFGE analysis were applied
for the molecular characterization of clinical VREF iso-
lates to identify different clonal complexes with different
pulsotypes that were not related to outbreaks. However,
according to the results obtained through PFGE, four
multidrug-resistant clones of VREF were identified at
HIMFG; in addition, these VREF isolates were identified
at different periods. Therefore, these data suggest that
these clones have circulated endemically at HIMFG.
In the case of cluster II, the clones have evolved from
cluster II-B to cluster II-B1 due to the high similarity
(> 90%) observed via PFGE analysis and based on the ac-
quisition of three bands for B1, suggesting a mechanism
of horizontal gene transfer. The results obtained in this
study highlight the importance of monitoring circulating
VREF isolates in different wards of this institution to
efficiently control multidrug resistance and prevent out-
breaks of these clones.
Conclusion
Little is known about VREF isolates in Mexican hospitals.
In this study, the detected virulence genes (esp and hyl),
multidrug profiles and allelic patterns were associated with
clonal complex 17 VREF clinical isolates obtained from
pediatric patients at HIMFG. To our knowledge, this is
the first report describing clonal complex 17 VREF isolates
in a tertiary care center in Mexico City.
Multidrug resistance and genetic determinants of viru-
lence confer advantages in VREF in the colonization of
their hosts. The genome of E. faecium is highly plastic,
showing an ability to readily acquire genes involved in
environmental persistence, colonization and virulence,
favoring the selection of specific clonal complexes in a
hospital environment. Therefore, the prevention and
control of the propagation of nosocomial infections
caused by VREF is crucial for identifying new emergent
subclones that could be challenging to treat in subse-
quent years.
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